cdmo.directory
← Compare landing

Ajinomoto Bio-Pharma Services vs Sterling Pharma Solutions

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/ajibio-pharma/sterlingpharmasolutions

CategoryAjinomoto Bio-Pharma ServicesSterling Pharma Solutions
Listed sitecdmocdmo
SummaryAjinomoto Bio-Pharma Services is a global contract development and manufacturing organization (CDMO) dedicated to improving the health of humankind through adaptive solutions and responsive service.Small molecule CDMO offering comprehensive API development and manufacturing from discovery through commercial cGMP production, with specialized expertise in complex and hazardous chemistries and ADC bioconjugation.
Services
  • Process Development
  • Small Molecule Development & Manufacturing
  • Biologics Development & Manufacturing
  • Peptide Manufacturing
  • Oligonucleotide Manufacturing
  • ADC (Antibody-Drug Conjugate) Manufacturing
  • Quality Control Testing
  • CMC Analytical Development
  • API Synthesis & Manufacturing
  • HPAPI Manufacturing (High-Potency)
  • Controlled Substance Manufacturing
  • Peptide Manufacturing
  • ADC (Antibody-Drug Conjugate) Manufacturing
  • ADC Payload & Linker Synthesis
  • Flow Chemistry & Continuous Manufacturing
  • Solid-State Chemistry & Polymorph Screening
  • CMC Analytical Development
  • Process Development
  • CMC Regulatory Submission Support
  • Bioconjugation Services
  • Small Molecule Development & Manufacturing
  • Quality Control Testing
  • Technology Transfer
Modalities
  • Small Molecule
  • Biologics (Other)
  • Antibody-Drug Conjugate (ADC)
  • Oligonucleotide
  • Gene Therapy
  • Peptide
  • Small Molecule
  • Antibody-Drug Conjugate (ADC)
  • Peptide
IndicationsData not yet provided.Data not yet provided.
Locations
  • Belgium, Belgium, Belgium
  • United States, United States
  • Japan, Japan
  • India, India
  • Cork, Cork, Munster, Ireland
  • Cramlington, Cramlington, Northumberland, United Kingdom
  • Deeside, Deeside, Wales, United Kingdom
  • Newcastle Biosphere, Newcastle, Tyne and Wear, United Kingdom
  • North Carolina, North Carolina, North Carolina, United States
  • Wisconsin, Wisconsin, Wisconsin, United States
  • North Carolina, North Carolina, North Carolina, US
  • Wisconsin, Wisconsin, Wisconsin, US
  • Newcastle Biosphere, Newcastle, England, UK
  • North Carolina, North Carolina, US
  • Wisconsin, Wisconsin, US
  • Cramlington, Cramlington, England, UK
  • North Carolina, North Carolina, North Carolina, USA
  • Wisconsin, Wisconsin, Wisconsin, USA
CertificationsData not yet provided.
  • FDA · Identifier: cGMP inspection
  • HPRA · Identifier: cGMP inspection (mutually recognised by FDA)
  • PMDA · Identifier: Project specific inspection
  • ANVISA · Identifier: Project specific inspection
  • MHRA · Identifier: cGMP inspection
  • DEA · Identifier: Schedule I-V controlled substances approval
  • ISO · Identifier: ISO/IEC 27001:2022, ISO/IEC 9001:2015, ISO 45001:2018, ISO 14001:2015
  • FDA · Identifier: cGMP inspection January 2017
  • PMDA · Identifier: project specific inspection June 2022
  • HPRA · Identifier: cGMP inspection March 2022
  • ANVISA · Identifier: project specific inspection 2021
  • MHRA · Identifier: cGMP inspection June 2021
  • FDA · Identifier: cGMP inspection May 2018
  • MHRA · Identifier: cGMP inspection April 2023
  • FDA · Identifier: Registered as bulk API manufacturer
  • DEA · Identifier: Approved to import, store, manufacture and export Schedule I-V controlled substances
  • FDA · Identifier: cGMP inspection March 2024
  • cGMP · Identifier: cGMP accreditation
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.